MusclePharm Corporation
MSLPQ
$0.00
$0.000.00%
| 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -0.15% | -33.63% | -25.58% | -12.27% | -19.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.15% | -33.63% | -25.58% | -12.27% | -19.16% |
| Cost of Revenue | 22.90% | 2.34% | 7.85% | 5.99% | -17.42% |
| Gross Profit | -59.09% | -110.97% | -99.42% | -56.26% | -23.29% |
| SG&A Expenses | 16.74% | -6.90% | -17.68% | -15.34% | -19.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.26% | -0.11% | 0.82% | 0.05% | -18.05% |
| Operating Income | -1,011.76% | -475.89% | -527.90% | -598.00% | -50.64% |
| Income Before Tax | -6,803.19% | -349.32% | -658.88% | -871.43% | 347.37% |
| Income Tax Expenses | -- | 42.17% | 60.00% | -68.18% | -- |
| Earnings from Continuing Operations | -6,803.19% | -340.28% | -680.09% | -789.72% | 256.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6,803.19% | -340.28% | -680.09% | -789.72% | 256.67% |
| EBIT | -1,011.76% | -475.89% | -527.90% | -598.00% | -50.64% |
| EBITDA | -786.52% | -438.07% | -469.27% | -451.91% | -48.70% |
| EPS Basic | -6,839.29% | -333.02% | -674.63% | -775.32% | 255.56% |
| Normalized Basic EPS | -5,810.00% | -579.53% | -1,206.06% | -854.55% | -185.71% |
| EPS Diluted | -9,147.62% | -343.53% | -1,300.00% | -775.32% | 216.67% |
| Normalized Diluted EPS | -7,780.00% | -579.53% | -1,759.09% | -854.55% | -114.29% |
| Average Basic Shares Outstanding | 0.81% | 3.14% | 1.15% | 1.90% | 2.03% |
| Average Diluted Shares Outstanding | -26.61% | 3.14% | -32.00% | 1.90% | 40.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
